![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Emergent BioSolutions Inks $174 Million COVID-19 Manufacturing Contract With AstraZeneca
Emergent BioSolutions Inks $174 Million COVID-19 Manufacturing Contract With AstraZeneca
![100Bills_flatmoney.gif](https://www.fdanews.com/ext/resources/test/Drug-Images3/100Bills_flatmoney.gif?t=1578960048&width=430)
Maryland-based Emergent BioSolutions has secured a $174 million contract with AstraZeneca for large-scale manufacturing of drug substances for the UK company’s COVID-19 vaccine.
Emergent will provide contract development and manufacturing services at its Baltimore Bayview facility for the commercial supply of the vaccine.
The new agreement expands upon an $87 million contract the companies signed in June.
Upcoming Events
-
21Oct